Strides Shasun today said it has received approval from the US health regulator for pain reliever drug ibuprofen.
The product will be marketed by Strides Pharma Inc in the US market under its OTC brand Nuprin, Strides Shasun said in a BSE filing.
Quoting IRi data, Strides Shasun said the US market for ibuprofen tablets USP 200mg is approximately USD 520 million.
Strides Shasun stock was trading 4.56 per cent higher at Rs 946.60 on the BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content
